A Randomized Trial of Prenatal versus Postnatal Repair of Myelomeningocele
Source: View publication →
The MOMS trial demonstrated that prenatal surgical repair of myelomeningocele significantly improves motor and neurologic outcomes in children while reducing the need for cerebrospinal fluid shunting, albeit at the cost of increased maternal and fetal morbidity related to preterm delivery.
Key Findings
Study Design
Study Limitations
Clinical Significance
This landmark study established prenatal surgery as a viable and superior standard of care for selected fetuses with myelomeningocele, fundamentally shifting the management paradigm from postnatal to prenatal intervention for this condition to improve functional long-term outcomes.
Historical Context
Before this trial, myelomeningocele was managed exclusively with postnatal surgical closure. While early observational reports suggested that intrauterine intervention might prevent secondary neurologic damage from amniotic fluid exposure and mitigate Chiari II malformations, robust evidence from a randomized controlled trial was lacking until the MOMS trial provided the necessary data to validate the intervention's efficacy.
Guided Discussion
High-yield insights from every perspective
Explain the 'two-hit hypothesis' regarding the pathophysiology of myelomeningocele and how prenatal surgery addresses this mechanism differently than postnatal surgery.
Key Response
The first 'hit' is the failure of neural tube closure during the fourth week of gestation. The second 'hit' is the progressive damage caused by exposure of the neural elements to amniotic fluid and mechanical trauma in utero. Prenatal surgery aims to mitigate the 'second hit' by covering the spinal cord early, whereas postnatal surgery only addresses the defect after the secondary damage has already occurred.
What are the primary clinical benefits demonstrated by the MOMS trial for the infant, and what is the specific maternal morbidity risk that necessitates a mandatory mode of delivery for all future pregnancies?
Key Response
The trial showed a significant reduction in the need for ventriculoperitoneal shunting and improved motor function (walking without orthotics). However, the hysterotomy required for prenatal repair increases the risk of uterine dehiscence or rupture, requiring that all future deliveries be performed via scheduled Cesarean section before the onset of labor.
Critically analyze the impact of prenatal myelomeningocele repair on the Chiari II malformation. How did the trial measure this, and what were the implications for the neonate's respiratory and feeding status?
Key Response
The MOMS trial found that prenatal repair resulted in a significant reversal of hindbrain herniation (the hallmark of Chiari II). By restoring the pressure gradient and stopping CSF leak at the spinal level, the brainstem can relocate superiorly, potentially reducing the incidence of brainstem-related complications like stridor, apnea, and dysphagia.
The MOMS trial demonstrated clear neurologic benefits for the child, but at the cost of maternal morbidity. How should a multidisciplinary center standardize the counseling process to ensure an unbiased presentation of the trade-off between neonatal mobility and maternal reproductive risk?
Key Response
Counseling must balance the child's potential for independent ambulation and reduced shunt-related complications against maternal risks of PPROM, preterm birth, and lifelong uterine scarring. Practice-changing implications suggest this should only be offered at high-volume fetal centers where coordinated care between MFM, Neurosurgery, and Ethics committees is established.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The MOMS trial was stopped early by the Data and Safety Monitoring Board (DSMB) due to efficacy. Discuss the potential for 'overestimation of effect' in early-stopped trials and how this might influence the statistical confidence in the long-term (30-month) neurodevelopmental secondary outcomes.
Key Response
Trials stopped early for benefit are susceptible to the 'Winner's Curse,' where the treatment effect size is often exaggerated. While the primary outcomes (shunting/motor function) were robust, the early termination may have limited the precision of secondary neurodevelopmental data, such as the Bayley Scales of Infant Development scores, requiring long-term follow-up studies like MOMS2.
Despite the randomized design, the MOMS trial could not be blinded for the surgical intervention. How does the use of an 'independent, blinded examiner' for the 12-month and 30-month assessments protect the internal validity of the study, and what threats to validity remain?
Key Response
Using blinded assessors for the primary outcomes (Bayley scores and Motor Function) minimizes observer bias, which is the greatest threat in unblinded trials. However, 'unblinding' can occur if the examiner notices the maternal surgical scar or if parents inadvertently reveal the treatment group, potentially introducing subtle bias in performance-based testing.
Based on the findings of the MOMS trial and subsequent ACOG/SMFM consensus, what are the absolute contraindications for prenatal repair that must be maintained in clinical guidelines to ensure maternal safety?
Key Response
Current guidelines (e.g., ACOG Committee Opinion No. 720) emphasize that prenatal repair should only be offered when the fetus has a normal karyotype, the mother has a BMI < 35, and there is no risk of preterm labor. These strict criteria are necessary because the maternal risks of surgery (pulmonary edema, placental abruption, and uterine rupture) are only justified when the likelihood of a successful fetal outcome is high and maternal complications can be managed.
Clinical Landscape
Noteworthy Related Trials
Management of Myelomeningocele Study (MOMS) Follow-up
Tested
Prenatal myelomeningocele repair
Population
Children aged 30 months who participated in the original MOMS trial
Comparator
Postnatal repair
Endpoint
Neurodevelopmental and motor outcomes at 30 months
MOMS2 Trial
Tested
Prenatal myelomeningocele repair
Population
Children who underwent prenatal repair in the original MOMS trial
Comparator
Children who underwent postnatal repair in the original MOMS trial
Endpoint
Motor and cognitive function at school age
Fetoscopic vs Open MOMS Trial
Tested
Fetoscopic prenatal repair
Population
Fetuses with myelomeningocele
Comparator
Open prenatal repair
Endpoint
Maternal and fetal outcomes including shunt dependency
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis